Eli Lilly vs Roche: Founders, CEOs and History
Eli Lilly was founded in 1876 by Colonel Eli Lilly and is led by David A. Ricks. Roche was founded in 1896 by Fritz Hoffmann-La Roche and is led by Thomas Schinecker.
Company facts
Founders
Eli Lilly
Colonel Eli Lilly
Following his military service and early experiences in the apothecary trade, Lilly worked in various pharmaceutical and business ventures, eventually amassing enough capital to strike out on his own.
Roche
Fritz Hoffmann-La Roche
Fritz Hoffmann-La Roche (1868-1920) founded F. Hoffmann-La Roche & Co. in Basel on 1 October 1896, at age 28.
CEOs and their tenures
Eli Lilly
- Randall L. Tobias1993–1998
Chairman and Chief Executive Officer
Lilly launched Zyprexa and Humalog under him. Sidney Taurel succeeded him in 1998.
Source - Sidney Taurel1998–2008
Former Chair and CEO
Taurel's focus on targeted, personalized medicine anticipated the future direction of the pharmaceutical industry, shifting the company's research paradigm toward more precise and effective treatments.
Source - John C. Lechleiter2008–2016
Chairman, President and CEO
Lilly restructured and launched new products during his tenure. David Ricks became chief executive in 2017.
Source - David A. Ricks2017–present
Chair and Chief Executive Officer
Ricks's aggressive restructuring and cultural overhaul have been widely credited with revitalizing Eli Lilly's pipeline and driving a notable period of financial growth and market capitalization expansion.
Source
Roche
- Fritz Gerber1978–1998
Chairman and Chief Executive Officer
He bought a majority of Genentech in 1990 and Boehringer Mannheim in 1997. Franz Humer succeeded him as chief executive in 1998.
Source - Severin Schwan2008–2023
Chief Executive Officer
Serving as CEO from 2008 to 2023, he cemented Roche's absolute dominance in global oncology and highly advanced diagnostics before moving to Chairman of the Board.
Source - Thomas Schinecker2023–present
Chief Executive Officer
Under Schinecker, Roche returned to growth after the COVID testing decline: 2025 sales rose 7% at constant rates to ~$73.8 billion (CHF 61.5 billion) and 12 late-stage studies read out positively that year.
Source
Timeline: Eli Lilly and Roche side by side
1876Eli Lilly
Eli Lilly Founded
Colonel Eli Lilly founds the company in Indianapolis.
1896Roche
F. Hoffmann-La Roche Founded in Basel
Fritz Hoffmann-La Roche founds the enterprise in Basel, Switzerland, pioneering mass-manufactured, chemically standardized prescription pharmaceuticals.
1898Roche
Commercial Breakthrough with Sirolin
Roche launches non-prescription cough syrup Sirolin, achieving widespread international distribution and financing early clinical laboratories.
1923Eli Lilly
Insulin Commercialization
Lilly helps commercialize insulin at industrial scale, shaping its long-term diabetes identity.
1934Roche
First Industrial Synthesis of Vitamin C
Roche becomes the first company to mass-produce synthetic Vitamin C (Redoxon) at industrial scale, anchoring decades of high-margin global cash flow.
1950Eli Lilly
Antibiotic Expansion
The company expands through antibiotics and broader prescription medicines.
1963Roche
Launch of Valium (Diazepam)
Roche introduces Valium, which becomes the world's most widely prescribed psychotropic medication and establishes global pharmaceutical leadership.
1968Roche
Establishment of Roche Diagnostics
Roche launches its dedicated diagnostic division, laying the foundation to become the world's preeminent in-vitro diagnostics (IVD) provider.
1982Eli Lilly
Humulin Approved
Lilly introduces Humulin, one of the first recombinant DNA human insulin products.
1990Roche
Majority Stake in Genentech
Roche bought a majority stake in Genentech in 1990.
1997Roche
Boehringer Mannheim Acquired
Roche bought Corange, the parent of Boehringer Mannheim, in 1997 for about $11 billion.
2008Roche
Severin Schwan becomes CEO
Severin Schwan became CEO of F. Hoffmann-La Roche in 2008. Led Roche for 14 years; handed over to Thomas Schinecker in March 2023 and became chairman.
2009Roche
Full Acquisition of Genentech for $46.8 Billion
Roche completes its historic $46.8 billion buyout of American biotechnology pioneer Genentech, securing market leadership in oncology biologics.
2017Eli Lilly
David Ricks Becomes CEO
David A. Ricks becomes Chair, President, and CEO.
2018Roche
Foundation Medicine & Flatiron Health Acquisitions
Roche acquires Foundation Medicine and Flatiron Health, integrating real-world oncology data analytics and genomic profiling into personalized healthcare.
2019Eli Lilly
Loxo Oncology Acquired
Lilly bought the cancer-drug developer Loxo Oncology in 2019 for about $8 billion.
2022Eli Lilly
Mounjaro Approved
Mounjaro receives U.S. approval for type 2 diabetes, beginning a major growth cycle.
2023Eli Lilly
Zepbound Approved
Zepbound receives U.S. approval for chronic weight management.
2023Roche
Acquired Telavant
F. Hoffmann-La Roche acquired Telavant for $7.1 billion. Roche paid $7.1 billion upfront for Telavant to gain US and Japan rights to the anti-TL1A antibody RVT-3101 (afimkibart) for inflammatory bowel disease.
2025Eli Lilly
Revenue Reaches $65.179B
Lilly reports $65.179B in 2025 revenue and $20.640B in net income.
2025Eli Lilly
First $1 Trillion Drugmaker
Lilly's market value crosses $1 trillion on November 21, 2025, a first for a healthcare company.
2025Roche
Group Sales Reach CHF 61.5 Billion
Under CEO Thomas Schinecker, Roche delivers group sales of ~$73.8 billion (CHF 61.5 billion), driven by ~$57.2B (CHF 47.7B) in Pharmaceuticals and ~$16.6B (CHF 13.8B) in Diagnostics.
2026Eli Lilly
Foundayo Approved
FDA approves Foundayo (orforglipron), Lilly's oral GLP-1 pill for obesity, on April 1, 2026.
Acquisitions
Eli Lilly
- Morphic Holding2024$3.2B
- POINT Biopharma2023$1.4B
- Prevail Therapeutics2021$1B
- Loxo Oncology2019$8B
- Elizabeth Arden1971Undisclosed
Roche
- PathAI2026$1.1B
- 89bio2025$3.5B
- Telavant2023$7.1B
- Carmot Therapeutics2023$2.7B
- Foundation Medicine2018$2.4B
- ForSight VISION42017Undisclosed
Questions about Eli Lilly vs Roche
Who is the CEO of Eli Lilly and Company and F. Hoffmann-La Roche AG?
Eli Lilly and Company is led by David A. Ricks and F. Hoffmann-La Roche AG is led by Thomas Schinecker. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Eli Lilly and Company founded vs F. Hoffmann-La Roche AG?
Eli Lilly and Company was founded in 1876 — 20 years before F. Hoffmann-La Roche AG, which was founded in 1896. Eli Lilly and Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger F. Hoffmann-La Roche AG.
How many employees does Eli Lilly and Company have compared to F. Hoffmann-La Roche AG?
Eli Lilly and Company employs approximately 50,000 people, while F. Hoffmann-La Roche AG employs approximately 112,774. F. Hoffmann-La Roche AG has the larger workforce at 112,774 employees, compared to Eli Lilly and Company's 50,000. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Eli Lilly and Company and F. Hoffmann-La Roche AG headquartered?
Eli Lilly and Company is headquartered in United States and F. Hoffmann-La Roche AG is headquartered in Switzerland. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded Eli Lilly and Company and F. Hoffmann-La Roche AG?
Eli Lilly and Company was founded by Colonel Eli Lilly. F. Hoffmann-La Roche AG was founded by Fritz Hoffmann-La Roche.
Which company has a longer operating history — Eli Lilly and Company or F. Hoffmann-La Roche AG?
Eli Lilly and Company has been operating for approximately 150 years, making it the more established of the two companies. F. Hoffmann-La Roche AG has been in operation for around 130 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Eli Lilly vs Roche overview